Intrapleural Fibrinolytic Therapy Guidelines

Standard Treatment Protocol

The British Thoracic Society recommends intrapleural fibrinolytics should be administered for 3 days, with streptokinase given at 250,000 IU twice daily or urokinase at 100,000 IU once daily 1, 2, 3
Streptokinase should be administered at 250,000 IU twice daily for 3 days, as recommended by the British Thoracic Society 1, 2, 3, 4
Urokinase should be administered at 100,000 IU once daily for 3 days, as recommended by the British Thoracic Society 1, 2, 3, 4

Evaluate treatment effectiveness at 5-8 days after initiating chest tube drainage and antibiotics, as recommended by the British Thoracic Society 1, 3
Resolution of fever and sepsis is a key indicator of successful therapy, according to the British Thoracic Society 1, 3

Discuss with a thoracic surgeon if effective pleural drainage has not been achieved by the 5-8 day assessment point, as recommended by the British Thoracic Society 1, 3

Patients receiving intrapleural streptokinase must be given a streptokinase exposure card and should receive urokinase or tissue plasminogen activator for any future systemic indications, as recommended by the British Thoracic Society 1, 2, 3, 4
Fever, particularly with streptokinase, is a common adverse effect, according to the British Thoracic Society 1, 2
Rare bleeding complications, such as pleural hemorrhage or epistaxis, can occur with intrapleural fibrinolytic therapy, as reported by the British Thoracic Society 1, 2, 4

Do not continue fibrinolytic therapy indefinitely without reassessment—the standard 3-day course should prompt clinical evaluation, as recommended by the British Thoracic Society 1, 2
Ensure the chest tube is patent before attributing poor drainage to loculations; flush with 20-50 mL normal saline if blockage is suspected, as recommended by the British Thoracic Society 1, 2, 4
Do not delay surgical consultation beyond 5-8 days if drainage remains inadequate despite fibrinolytic therapy, as recommended by the British Thoracic Society 1, 3

The British Thoracic Society guidelines report that pleural pain (chest pain) is a recognized side effect, occurring in approximately 7% of patients receiving streptokinase versus 3% with placebo 5
Fever is commonly noted, particularly with streptokinase, though it can be difficult to distinguish from fever related to the underlying pleural infection itself 6, 5
Immunological reactions occur most frequently with streptokinase due to its antigenic properties 6, 5
Local pleural hemorrhage and systemic bleeding are rare but serious adverse effects, with isolated reports 6, 5
Nosebleeds (epistaxis) are a rare adverse effect 5
Transient disorientation without evidence of intracerebral bleeding has been reported 5
Cardiac arrhythmias with urokinase can occur due to histamine release 5
Adult respiratory distress syndrome (ARDS) has been reported in one case receiving both streptokinase and urokinase 5

Pleural pain from the fibrinolytic agent itself or the underlying infection is the expected complaint 5
Referred diaphragmatic pain to the shoulder can occur with any pleural process, but is related to the underlying pleural infection or irritation, not specifically to fibrinolytic therapy 6

Monitor for development or worsening of chest pain, which has a 7% incidence with streptokinase 5
Monitor for fever, particularly distinguishing new fever from baseline infection-related fever 6, 5
Monitor for signs of bleeding complications, though these are rare 5
Monitor for allergic reactions, especially with streptokinase 5

Allergic reactions are a recognized risk of intrapleural streptokinase because it is a bacterial‑derived antigenic protein. This safety concern is documented in clinical observations. 7
Cumulative intrapleural streptokinase doses up to 1.5 million IU have been investigated and did not produce systemic fibrinolysis. These data come from dose‑escalation studies. 7

The BTS/MRC Multicentre Intrapleural Streptokinase Trial demonstrated no clinical benefit of streptokinase in adult empyema, leading the British Thoracic Society to recommend against its routine use because of an unfavorable risk‑benefit profile compared with alternative fibrinolytics. This recommendation is based on a high‑quality randomized controlled trial (Level 1 evidence). [7][8]
If a patient receiving intrapleural streptokinase develops persistent fever, sepsis, or a radiological collection despite therapy, the British Thoracic Society advises prompt surgical consultation. This guidance reflects expert consensus (Level 3 evidence). [7][8]